AJP - Heart AJP: Gastrointestinal and Liver Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 294: H1503-H1504, 2008. First published February 22, 2008; doi:10.1152/ajpheart.00138.2008
0363-6135/08 $8.00
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/4/H1503    most recent
ajpheart.00138.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jovin, I. S.
Right arrow Articles by Giordano, F. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jovin, I. S.
Right arrow Articles by Giordano, F. J.

EDITORIAL FOCUS

Differentiation by association: is a cell's fate determined by the company it keeps?

Ion S. Jovin1 and Frank J. Giordano2

1Virginia Commonwealth University/Medical College of Virginia, Richmond, Virginia; and 2Yale University, New Haven, Connecticut

THE LOSS OF HEART MUSCLE during myocardial infarction is a major worldwide health issue, often leading to debilitating heart failure or death. Terminally differentiated cardiac muscle retains little if any capacity to undergo mitosis, and thus substantive regeneration of the heart after infarction does not occur. As such, mining the pluripotency of stem cells to regenerate lost heart muscle is an extremely attractive concept (6). A recent PubMed search for "heart and stem cell" yielded ~3,000 publications over the past five years, evidencing a remarkable investigational focus on cell therapy to rebuild damaged hearts. Many of these studies document significantly better cardiac function when cells are delivered to the heart after infarction (12, 21), and the field has rapidly moved to clinical testing (2, 15, 17, 27). Despite this widespread enthusiasm and hope, the evidence that stem cells delivered to the heart become mature contractile cardiac muscle is scant and controversial.

In the search for the "holy grail" of cardiac regeneration, several alternative paths have been taken. These include attempts to find the right marrow-derived cell population, use of cord blood-derived cells (10), use of cells derived from adipose tissue or other noncardiac somatic tissue source (4, 24), use of embryonic stem cells (11), attempts to identify progenitor cell niches in the heart (13, 19), and several alternative strategies to direct stem cell differentiation into the heart muscle. Following this last path, Orlandi et al. (20) report an elegant study of the fate of umbilical cord hematopoietic stem cells cocultured with cardiac myocytes (20). In their study, these investigators cocultured cord blood-derived human CD34+ cells with mouse cardiomyocytes. To track the fate of the human cells, cells were first transduced with a lentivirus-encoding enhanced green fluorescent protein (EGFP). After a week in coculture, mononucleated EGFP+ cells underwent an extensive electrophysiological analysis that demonstrated multiple properties consistent with cardiac muscle differentiation, including action potential-associated cytosolic Ca2+ concentration ([Ca2+]i) transients, spontaneous sarcoplasmic reticulum [Ca2+]i oscillations, and membrane potential depolarization. These cells were also connected to surrounding cells by gap junctions.

Despite this functional and anatomical evidence of cardiac differentiation, RT-PCR of cocultured cells showed no expression of human-specific cardiac genes. There was, however, continued expression of human PGK1, providing evidence that the human cells remained viable and transcriptionally active. Thus, in this excellent well-controlled study, the authors convincingly demonstrate that functional measures alone are not sufficient to prove cardiac differentiation and, moreover, that physical association of CD34+ cells with cardiomyocytes does not induce full cardiac differentiation of these cells. These data strongly suggest that cardiac differentiation of stem cells is more than just a simple matter of association. The data do, however, suggest that physical contact between the CD34+ cells and cardiac myocytes is capable of inducing at least some phenotypic features of cardiac differentiation. Thus association seems to matter but is not a sufficient stimulus to impart full differentiation.

The data must, however, be interpreted in the context of the limitations of the study. As with all studies in which cardiac differentiation of stem cells purportedly occurs in association with fully differentiated cardiomyocytes, the possibility of cellular fusion must be considered. To exclude fusion, the authors fastidiously studied only mononuclear EGFP+ cells, the assumption being that cytoplasmic fusion would yield binucleate cells. As the authors acknowledge, this does not rule out nuclear fusion, which was not assessed. Nonetheless, even if the assumption of nuclear fusion is made, other questions arise. What determines which genes will be expressed within fused nuclei? Why did the constitutive expression of a noncardiac human gene continue, whereas no expression of human cardiac genes was observed? These questions are representative of the myriad of questions still unanswered in the field of regenerative medicine and reflect the immense complexity of the biology involved.

Among the unanswered questions are those of how cell-cell contact and the cellular microenvironment contribute to cell fate determination. Stem cells express integrins and other transmembrane proteins with extracellular domains, and these may play an essential role in transducing signals from the microenvironment into fate-determining biological events in the stem cells (3, 14, 16, 30). Cell-cell contact with stromal cells has been shown to induce marked alterations in gene expression in stem cells and to alter their proliferation (29). Paracrine signals in the microenvironment likely also play a critical role in determining cell fate (8), as may specific physical parameters such as oxygen tension (1). In addition to all of these considerations, it must be remembered that although they are distinctly different cell types, the DNA instruction set within a cardiac muscle cell is the same as is found in a retinal rod, or a Purkinje cell in the cerebellum. Much of the information that defines which genes will be expressed in each of these unique cell types is contained in epigenetic determinants such as DNA methylation patterns and histone acetylation (5, 23). These epigenetic determinants of cell fate are still poorly understood (25, 26, 28), and in a very real sense the same biological complexities that have vexed cancer biologists trying to understand malignant transformation are confronting the regenerative medicine biologists trying to push cells toward specific differentiation pathways.

Still, among all this complexity, progress is being made. In an intriguing attempt to provide the optimal environment for the generation of heart muscle from cells, a recent report described the use of decellularized hearts. In the reported study (22), rat hearts were decellularized by treatment with detergents, leaving essentially only the extracellular matrix scaffolding behind. When endothelial cells and neonatal cardiac myocytes were introduced into these decellularized hearts, followed by incubation in a bioreactor, they organized into an endothelialized vasculature and enough cardiac muscle to allow cardiac contraction and force generation. Although this study did not use stem cells, the possibility of using this type of advanced tissue scaffolding in conjunction with pluripotent cells is an exciting consideration.

The current study by Orlandi et al. (20) is significant because it very elegantly demonstrates that the "differentiation by association" paradigm is oversimplistic. Ultimately, studies such as theirs clarify that there is still much science to be done, and this will help advance the field. As a closing note, even though we currently do not appear to know enough to push cellular differentiation down the pathways we chose, cell therapy may still be beneficial in the heart by other mechanisms. Cardiac myocytes are a major source of autocrine and paracrine factors produced in the heart (7), and this capacity can be markedly diminished by the loss of heart muscle during infarction. Interestingly, it may actually be the repletion of these paracrine factors by cells delivered to the heart after infarction that is primarily responsible for the beneficial effects that have been observed (9, 18).

FOOTNOTES


Address for reprint requests and other correspondence: F. J. Giordano, Center for Vascular Biology and Transplantation, Yale School of Medicine, 10 Amistad St., Rm. 426, New Haven, CT 06520 (e-mail: frank.giordano{at}yale.edu)

REFERENCES

  1. Annabi B, Lee YT, Turcotte S, Naud E, Desrosiers RR, Champagne M, Eliopoulos N, Galipeau J, Beliveau R. Hypoxia promotes murine bone-marrow-derived stromal cell migration and tube formation. Stem Cells 21: 337–347, 2003.[CrossRef][Web of Science][Medline]
  2. Assmus B, Honold J, Schachinger V, Britten MB, Fischer-Rasokat U, Lehmann R, Teupe C, Pistorius K, Martin H, Abolmaali ND, Tonn T, Dimmeler S, Zeiher AM. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 355: 1222–1232, 2006.[Abstract/Free Full Text]
  3. Campos LS. Beta1 integrins and neural stem cells: making sense of the extracellular environment. Bioessays 27: 698–707, 2005.[CrossRef][Web of Science][Medline]
  4. Case J, Horvath TL, Ballas CB, March KL, Srour EF. In vitro clonal analysis of murine pluripotent stem cells isolated from skeletal muscle and adipose stromal cells. Exp Hematol 36: 224–234, 2008.[Web of Science][Medline]
  5. Cheng LC, Tavazoie M, Doetsch F. Stem cells: from epigenetics to microRNAs. Neuron 46: 363–367, 2005.[CrossRef][Web of Science][Medline]
  6. Dimmeler S, Zeiher AM, Schneider MD. Unchain my heart: the scientific foundations of cardiac repair. J Clin Invest 115: 572–583, 2005.[CrossRef][Web of Science][Medline]
  7. Giordano FJ, Gerber HP, Williams SP, VanBruggen N, Bunting S, Ruiz-Lozano P, Gu Y, Nath AK, Huang Y, Hickey R, Dalton N, Peterson KL, Ross J Jr, Chien KR, Ferrara N. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci USA 98: 5780–5785, 2001.[Abstract/Free Full Text]
  8. Grassel S, Ahmed N. Influence of cellular microenvironment and paracrine signals on chondrogenic differentiation. Front Biosci 12: 4946–4956, 2007.[CrossRef][Web of Science][Medline]
  9. Guan K, Hasenfuss G. Do stem cells in the heart truly differentiate into cardiomyocytes? J Mol Cell Cardiol 43: 377–387, 2007.[CrossRef][Web of Science][Medline]
  10. Harris DT, Rogers I. Umbilical cord blood: a unique source of pluripotent stem cells for regenerative medicine. Curr Stem Cell Res Ther 2: 301–309, 2007.[Medline]
  11. Laflamme MA, Gold J, Xu C, Hassanipour M, Rosler E, Police S, Muskheli V, Murry CE. Formation of human myocardium in the rat heart from human embryonic stem cells. Am J Pathol 167: 663–671, 2005.[Abstract/Free Full Text]
  12. Lanza R, Moore MA, Wakayama T, Perry AC, Shieh JH, Hendrikx J, Leri A, Chimenti S, Monsen A, Nurzynska D, West MD, Kajstura J, Anversa P. Regeneration of the infarcted heart with stem cells derived by nuclear transplantation. Circ Res 94: 820–827, 2004.[Abstract/Free Full Text]
  13. Laugwitz KL, Moretti A, Caron L, Nakano A, Chien KR. Islet1 cardiovascular progenitors: a single source for heart lineages? Development 135: 193–205, 2008.[Abstract/Free Full Text]
  14. Levesque JP, Simmons PJ. Cytoskeleton and integrin-mediated adhesion signaling in human CD34+ hemopoietic progenitor cells. Exp Hematol 27: 579–586, 1999.[CrossRef][Web of Science][Medline]
  15. Losordo DW, Schatz RA, White CJ, Udelson JE, Veereshwarayya V, Durgin M, Poh KK, Weinstein R, Kearney M, Chaudhry M, Burg A, Eaton L, Heyd L, Thorne T, Shturman L, Hoffmeister P, Story K, Zak V, Dowling D, Traverse JH, Olson RE, Flanagan J, Sodano D, Murayama T, Kawamoto A, Kusano KF, Wollins J, Welt F, Shah P, Soukas P, Asahara T, Henry TD. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation 115: 3165–3172, 2007.[Abstract/Free Full Text]
  16. Lutolf MP, Hubbell JA. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat Biotechnol 23: 47–55, 2005.[CrossRef][Web of Science][Medline]
  17. Metharom P, Doyle B, Caplice NM. Clinical trials in stem cell therapy: pitfalls and lessons for the future. Nat Clin Pract Cardiovasc Med 4, Suppl 1: S96–S99, 2007.[CrossRef][Medline]
  18. Murry CE, Reinecke H, Pabon LM. Regeneration gaps: observations on stem cells and cardiac repair. J Am Coll Cardiol 47: 1777–1785, 2006.[Abstract/Free Full Text]
  19. Oh H, Bradfute SB, Gallardo TD, Nakamura T, Gaussin V, Mishina Y, Pocius J, Michael LH, Behringer RR, Garry DJ, Entman ML, Schneider MD. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci USA 100: 12313–12318, 2003.[Abstract/Free Full Text]
  20. Orlandi A, Pagani F, Avitabile D, Bonanno G, Scambia G, Vigna E, Grassi F, Eusebi F, Fucile S, Pesce M, Capogrossi M. Functional properties of cells obtained from human cord blood CD34+ stem cells and mouse cardiac myocytes in coculture. Am J Physiol Heart Circ Physiol (January 25, 2008); doi:10.1152/ajpheart.01285.2007.[Abstract/Free Full Text]
  21. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, Anversa P. Bone marrow cells regenerate infarcted myocardium. Nature 410: 701–705, 2001.[CrossRef][Medline]
  22. Ott HC, Matthiesen TS, Goh SK, Black LD, Kren SM, Netoff TI, Taylor DA. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat Med 14: 213–221, 2008.[CrossRef][Web of Science][Medline]
  23. Postovit LM, Seftor EA, Seftor RE, Hendrix MJ. A three-dimensional model to study the epigenetic effects induced by the microenvironment of human embryonic stem cells. Stem Cells 24: 501–505, 2006.[CrossRef][Web of Science][Medline]
  24. Rehman J, Traktuev D, Li J, Merfeld-Clauss S, Temm-Grove CJ, Bovenkerk JE, Pell CL, Johnstone BH, Considine RV, March KL. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 109: 1292–1298, 2004.[Abstract/Free Full Text]
  25. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 447: 425–432, 2007.[CrossRef][Medline]
  26. Sasaki H, Matsui Y. Epigenetic events in mammalian germ-cell development: reprogramming and beyond. Nat Rev Mol Cell Biol 9: 129–140, 2008.
  27. Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Suselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 355: 1210–1221, 2006.[Abstract/Free Full Text]
  28. Schulz WA, Hoffmann MJ. Transcription factor networks in embryonic stem cells and testicular cancer and the definition of epigenetics. Epigenetics 2: 37–42, 2007.[Medline]
  29. Wagner W, Saffrich R, Wirkner U, Eckstein V, Blake J, Ansorge A, Schwager C, Wein F, Miesala K, Ansorge W, Ho AD. Hematopoietic progenitor cells and cellular microenvironment: behavioral and molecular changes upon interaction. Stem Cells 23: 1180–1191, 2005.[CrossRef][Web of Science][Medline]
  30. Watt FM. Role of integrins in regulating epidermal adhesion, growth and differentiation. EMBO J 21: 3919–3926, 2002.[CrossRef][Web of Science][Medline]




This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/4/H1503    most recent
ajpheart.00138.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jovin, I. S.
Right arrow Articles by Giordano, F. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jovin, I. S.
Right arrow Articles by Giordano, F. J.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.